Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer

Abstract

Summary T lymphocytes, activated by interleukin 2 during an anti-tumour response, release soluble interleukin 2 receptors (slL-2R) into the bloodstream. We analysed the prognostic value of the serum slL-2R level in gastric cancer. Serum concentration of slL-2R in 96 gastric cancer patients and 100 healthy control subjects' was measured by enzyme-linked immunosorbent assay. All survivors were followed for more than 50 months. Serum slL-2R level was considered with respect to prognosis, clinicopathological factors, other tumour markers and peripheral blood cell count. Stage IlIl and IV patients had significantly higher slL-2R levels than lower stage patients and control subjects. Stage Ill and IV gastric cancer patients were divided into 'high' and 'low' slL-2R groups based upon the control subjects' serum slL-2R mean value plus one standard deviation. The high group had a significantly worse prognosis than the low group, although clinicopathological features and treatments were similar. Multivariate analysis demonstrated that the serum slL-2R level is an independent indicator. The sIL-2R level did not correlate with carbohydrate antigen 19-9, however it did correlate with carcinoembryonic antigen (r= 0.22) and with numbers of peripheral blood monocytes (r= 0.54). In conclusion, serum slL-2R may predict the outcome of gastric cancer patients with stage IlIl or IV disease.

The Prognostic Significance of Pretreatment Serum CEA Levels in Gastric Cancer: A Meta-Analysis Including 14651 Patients

“…The multivariate-adjusted HRs and 95% CIs were directly obtained from 20 studies [38,39,40,24,41,13,25,42,20,43,21,44,45,46,47,37,48,49,29,50]. Based on the multivariate-adjusted HRs, the meta-analyses were performed in terms of OS, DSS and DFS.…”

Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging

“…Serum levels of this peptide have been estimated in many disease entities including malignancies, diseases of autoaggression and inflammation/infectious-based processes, where sIL-2R serum concentration frequently correlated with disease severity (De Rie et al 1996, Itoh et al 1998, Kami et al 2000, Kapp et al 1988, Matsumoto et al 1998, Nakata et al 1998, Niitsu et al 2001, Spadaro et al 2001, Suenaga et al 1998, Tartour et al 2001, Vonderheid et al 1998). Monitoring of sIL-2R serum levels is a useful method for the assessment of disease intensity, efficacy of provided treatment, and for prediction of further illness course.…”

Emerging Role of Interleukins in Cancer Treatment

“…Similar studies in various solid tumor cases have also shown sIL-2R to be an adverse prognostic feature, especially in patients with nasopharyngeal cancer [34,35], colorectal cancer [36,37], breast cancer [38], ovarian cancer [39][40][41], gastric cancer [42,43], lung cancer [44,45] and leukemia [46,47], respectively. IL-2 has been introduced as a cancer treatment since 1992.…”